AR049560A2 - CRYSTAL FORMS OF (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETILE) AMIN 3-HYDROXY-5- (2- (1-TETRAHYDROPIRIMID-2-ONIL) -3-METHYLBUTANOL) AMIN-1,6- DIFENILHEXANO (LOPINAVIR) - Google Patents

CRYSTAL FORMS OF (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETILE) AMIN 3-HYDROXY-5- (2- (1-TETRAHYDROPIRIMID-2-ONIL) -3-METHYLBUTANOL) AMIN-1,6- DIFENILHEXANO (LOPINAVIR)

Info

Publication number
AR049560A2
AR049560A2 ARP050102702A ARP050102702A AR049560A2 AR 049560 A2 AR049560 A2 AR 049560A2 AR P050102702 A ARP050102702 A AR P050102702A AR P050102702 A ARP050102702 A AR P050102702A AR 049560 A2 AR049560 A2 AR 049560A2
Authority
AR
Argentina
Prior art keywords
amin
lopinavir
hydroxy
tetrahydropirimid
dimethylphenoxiacetile
Prior art date
Application number
ARP050102702A
Other languages
Spanish (es)
Inventor
Daniel Dickman
Sanjay Chemburkar
James Fort
Rodger Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049560(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR049560A2 publication Critical patent/AR049560A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formas cristalinas hidratadas, las formas cristalinas solvatadas y las formas cristalinas de (2S, 3S, 5S)-2-(2,6-dimetilfenoxiacetil) amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoil)amin-1,6-difenilhexano (lopinavir), asi como las formas substancialmente puras de todas las formas anteriormente mencionadas. El lopinavir es de utilidad en la inhibicion de la proteasa del VIH y la inhibicion de una infeccion por VIH.Hydrated crystalline forms, solvated crystalline forms and crystalline forms of (2S, 3S, 5S) -2- (2,6-dimethylphenoxyacetyl) amin-3-hydroxy-5- (2- (1-tetrahydropyrimid-2-onyl) -3-methylbutanoyl) amin-1,6-diphenylhexane (lopinavir), as well as substantially pure forms of all the aforementioned forms. Lopinavir is useful in inhibiting HIV protease and inhibiting HIV infection.

ARP050102702A 2000-03-30 2005-06-29 CRYSTAL FORMS OF (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETILE) AMIN 3-HYDROXY-5- (2- (1-TETRAHYDROPIRIMID-2-ONIL) -3-METHYLBUTANOL) AMIN-1,6- DIFENILHEXANO (LOPINAVIR) AR049560A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
AR049560A2 true AR049560A2 (en) 2006-08-16

Family

ID=27065762

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010101522A AR033360A1 (en) 2000-03-30 2001-03-29 CRYSTAL FORMS OF (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETILE) AMIN-3-HIDROXI-5- (2- (1-TETRAHYDROPIRIMID-2-ONIL) -3-METHYLBUTANOIL) AMIN-1,6 -DIFENILHEXANO (LOPINAVIR)
ARP050102702A AR049560A2 (en) 2000-03-30 2005-06-29 CRYSTAL FORMS OF (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETILE) AMIN 3-HYDROXY-5- (2- (1-TETRAHYDROPIRIMID-2-ONIL) -3-METHYLBUTANOL) AMIN-1,6- DIFENILHEXANO (LOPINAVIR)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010101522A AR033360A1 (en) 2000-03-30 2001-03-29 CRYSTAL FORMS OF (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETILE) AMIN-3-HIDROXI-5- (2- (1-TETRAHYDROPIRIMID-2-ONIL) -3-METHYLBUTANOIL) AMIN-1,6 -DIFENILHEXANO (LOPINAVIR)

Country Status (22)

Country Link
EP (1) EP1268442A2 (en)
JP (1) JP2003529592A (en)
KR (1) KR100773258B1 (en)
CN (2) CN1330639C (en)
AR (2) AR033360A1 (en)
AU (3) AU2001250920B2 (en)
BG (1) BG107165A (en)
BR (1) BR0109433A (en)
CA (1) CA2403635A1 (en)
CZ (1) CZ20023529A3 (en)
HU (1) HUP0302675A3 (en)
IL (1) IL151551A0 (en)
MX (1) MXPA02009559A (en)
MY (1) MY128296A (en)
NO (1) NO325005B1 (en)
NZ (1) NZ521183A (en)
PE (1) PE20011232A1 (en)
PL (1) PL359727A1 (en)
SA (2) SA01220270B1 (en)
SK (1) SK14832002A3 (en)
TW (1) TWI284640B (en)
WO (1) WO2001074787A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8445506B2 (en) 2009-02-06 2013-05-21 Hetero Research Foundation Polymorphs of lopinavir
CN102470158A (en) * 2009-08-27 2012-05-23 默沙东公司 Processes for preparing protease inhibitors of hepatitis c virus
CN112830899A (en) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 Novel lopinavir crystal form and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
KR20030011807A (en) 2003-02-11
SA06270303B1 (en) 2009-08-02
CN101066952A (en) 2007-11-07
PE20011232A1 (en) 2001-12-08
MXPA02009559A (en) 2003-05-21
CN1330639C (en) 2007-08-08
JP2003529592A (en) 2003-10-07
WO2001074787A2 (en) 2001-10-11
NO20024679D0 (en) 2002-09-30
HUP0302675A3 (en) 2004-03-29
MY128296A (en) 2007-01-31
CA2403635A1 (en) 2001-10-11
CZ20023529A3 (en) 2003-02-12
NO325005B1 (en) 2008-01-14
AR033360A1 (en) 2003-12-17
NZ521183A (en) 2004-03-26
IL151551A0 (en) 2003-04-10
TWI284640B (en) 2007-08-01
KR100773258B1 (en) 2007-11-05
NO20024679L (en) 2002-09-30
AU2001250920B2 (en) 2006-06-29
HUP0302675A2 (en) 2003-12-29
BG107165A (en) 2003-07-31
BR0109433A (en) 2004-08-10
AU2006222711A1 (en) 2006-10-19
PL359727A1 (en) 2004-09-06
AU5092001A (en) 2001-10-15
CN1422259A (en) 2003-06-04
SK14832002A3 (en) 2003-02-04
SA01220270B1 (en) 2006-11-14
EP1268442A2 (en) 2003-01-02
WO2001074787A3 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
ATE367394T1 (en) ENHANCEMENT IN THE CELL OF PHOSPHONATE ANALOGUES OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS THEMSELVES
CL2009001844A1 (en) Solid pharmaceutical dosage form comprising lopinavir and ritonavir formulated in the form of a solid dispersion or solid solution, a water soluble polymer and a surfactant with hlb values between 4 and 10, useful in the treatment of an HIV infection (divisional sol 393-06).
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
AR049560A2 (en) CRYSTAL FORMS OF (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETILE) AMIN 3-HYDROXY-5- (2- (1-TETRAHYDROPIRIMID-2-ONIL) -3-METHYLBUTANOL) AMIN-1,6- DIFENILHEXANO (LOPINAVIR)
SE0102315D0 (en) Compounds
BR0012752A (en) Benzofuryl piperazines and benzofuril homopiperazines: serotonin agonists
CO5570678A2 (en) N-ALQUILO-4-METILENEAMINO-3-HIDROXILO-2-PIRIDONAS AS ANTI- MICROBIALS
UY26380A1 (en) FAB I INHIBITORS
EA200301115A1 (en) CRYSTAL FORMS OF AZITROMYCIN
ATE373005T1 (en) THIENOPYRROLES AS ANTIVIRAL AGENTS
CO5540347A2 (en) DIPEPTIDE DERIVATIVES CONTAINING A 2-TERMINAL N-TERMINAL GROUP AS VASOPEPTIDASE INHIBITORS
NO20052788L (en) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
DE60218633D1 (en) INHIBITORS OF CRUCIPAIN AND OTHER CYSTONE PROTEASES
EA200701692A1 (en) HIV PROTEASE INHIBITORS
DE60221508D1 (en) Amino acid derivatives as HIV protease inhibitors
EP1947094A3 (en) Process for the preparation of taxane derivatives
ATE499837T1 (en) ANTIMICROBIAL COMPOSITIONS CONTAINING ETHANOLAMIDE BUFFER AND BIGUANIDE DISINFECTANTS
PE74799A1 (en) ANTIVIRAL COMBINATIONS
PT1244614E (en) TRIPTASE INHIBITORS
AR013087A1 (en) FORM V OF AMPRENAVIR, ITS USE AS ANTIVIRAL COMPOUND, A PROCESS TO PREPARE IT, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT
UY27033A1 (en) NEW COMPOUNDS FOR USE AS INHIBITORS OF HIV PROTEASE
TH22511A (en) USE OF QUINOXALINES IN COMBINATION WITH PROTEASE INHIBITORS AS MEDICAMENTS FOR TREATION, AIDS AND / OR HIV INFECTIONS
DE602005010869D1 (en) PEPTIDOMIMETIC INHIBITORS OF HIV PROTEASE

Legal Events

Date Code Title Description
FB Suspension of granting procedure